Monrol and ImaginAb Announce Supply, Manufacturing and Distribution Partnership
Inglewood, California and Istanbul, Turkey – June 9, 2022 - ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radioligand therapy (RLT), is delighted to announce that it has reached an agreement, in principle with Turkey-based Radiopharmaceuticals company, Monrol, for the supply of radioisotopes, Zirconium-89 (Zr-89) and Lutetium-177 nca (Lu-177), in diagnostic imaging and radiopharmaceutical therapy, respectively.
In addition, Monrol will manufacture and distribute ImaginAb’s proprietary investigational CD8 ImmunoPET agent, Zirconium 89Zr-crefmirlimab berdoxam, initially providing support on ImaginAb’s Phase IIb iPREDICT clinical study and additional partner pharmaceutical company studies and investigator-initiated trials. The agreement allows for the manufacture and distribution of the agent to continue post regulatory approval.
Lu-177 will initially be supplied to support ImaginAb’s IND-enabling studies and subsequent clinical trials for the Company’s emerging RPT pipeline.
Monrol General Manager Aydın Küçük,said: “We are delighted to be working with ImaginAb to supply, manufacture and distribute innovative radiopharmaceutical products for the Company’s proprietary CD8 ImmunoPET imaging technology as we continue our mission to improve quality of life for cancer patients and transform patient care for the future.”
Dr Gareth Smith, General Manager for Europe at ImaginAb, added: “ImaginAb is thrilled to be partnering with Monrol, a company with a broad set of offerings to support our development programs and pipeline. We look forward to rolling out the supply of high quality radioisotopes to our clinical trial patients in Europe and to those in Australia in the near future”.